The poor survival benefit of anti‐EGFR therapy in the right‐sided tumor group may result in a small prognostic benefit, and as a result, the antitumor effect of the increase in the number of drugs administered on the OS of patients with right‐sided tumors was poor. Here, EGFR is linked to neoplasm.